ArticleBMC neurology2025
Incomplete penetrance and variable phenotypes of a novel NPRL2 frameshift variant: from familial focal epilepsy with variable foci 2 to neurodevelopmental disorders.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundFamilial focal epilepsy with variable foci 2 (FFEVF2), an autosomal dominant disorder caused by pathogenic heterozygous variants in the NPRL2 gene, is characterized by focal epilepsy originating in different cortical regions of the temporal, frontal, parietal, and occipital lobes of the brain.
methodsThe study included a Chinese family in which proband had epilepsy, and her brother had autism, attention deficit hyperactivity disorder (ADHD), and mild intellectual disability (ID). Blood samples of the two children and their parents were collected for whole exome sequencing (WES).
resultsProband was a 1-month-and-7-day-old baby girl with epilepsy manifesting as focal to bilateral tonic-clonic seizures and cranial magnetic resonance imaging showing focal cortical dysplasia or subcortical grey matter ectopia in the left anterior and posterior central gyrus. WES revealed a heterozygous variant of the NPRL2 gene [c.907delC (p. Gln303Serfs*11)]. Sanger sequencing confirmed that the variant was inherited from her unaffected mother. According to the ACMG, the variant was classified as likely pathogenic. Finally, she was diagnosed with FFEVF2. Her epilepsy type was only reported in one patient with FFEVF2 with multiple seizure types. Follow-up revealed that she had a global developmental delay and absent language, and despite numerous antiseizure medications, her seizures were uncontrolled. Her brother carried the same mutated gene, which manifested primarily as autism, ADHD, speech deficit, and mild ID. So far, he has had no seizures and a negative electroencephalogram. But he could have seizures in the future, and it’s worth following up.
conclusionThis study describes a family with a new NPRL2 variant, where affected members exhibited various neurological disorders including FFEVF2, autism, and ADHD, demonstrating incomplete penetrance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.